<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36979336</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>21</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Role of Altered Metabolism of Triglyceride-Rich Lipoprotein Particles in the Development of Vascular Dysfunction in Systemic Lupus Erythematosus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">401</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom13030401</ELocationID><Abstract><AbstractText Label="BACKGROUND">Impaired lipid metabolism contributes to accelerated inflammatory responses in addition to promoting the formation of atherosclerosis in systemic lupus erythematosus (SLE). We aimed to evaluate the lipid profile, inflammatory markers, and vascular diagnostic tests in active SLE patients to clarify the association between dyslipidemia and early vascular damage.</AbstractText><AbstractText Label="PATIENTS AND METHODS">51 clinically active SLE patients and 41 age- and gender-matched control subjects were enrolled in the study. Lipoprotein subfractions were detected by Lipoprint. Brachial artery flow-mediated dilation and common carotid intima-media thickness were detected by ultrasonography. Arterial stiffness indicated by augmentation index (Aix) and pulse wave velocity was measured by arteriography.</AbstractText><AbstractText Label="RESULTS">We found significantly higher Aix, higher VLDL ratio, plasma triglyceride, ApoB100, and small HDL, as well as lower HDL-C, large HDL, and ApoA1 in patients with SLE. There was a significant positive correlation of Aix with triglyceride, VLDL, IDL-C, IDL-B, and LDL1. A backward stepwise multiple regression analysis showed IDL-C subfraction to be the best predictor of Aix.</AbstractText><AbstractText Label="CONCLUSIONS">Our results indicate that in young patients with SLE, triglyceride-rich lipoproteins influence vascular function detected by Aix. These parameters may be assessed and integrated into the management plan for screening cardiovascular risk in patients with SLE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Di&#xf3;szegi</LastName><ForeName>&#xc1;gnes</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Division of Metabolic Diseases, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#x151;rincz</LastName><ForeName>Hajnalka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Metabolic Diseases, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ka&#xe1;li</LastName><ForeName>Eszter</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine, V&#xe4;sterviks Sjukhus Hospital, 593 33 V&#xe4;sterviks, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solt&#xe9;sz</LastName><ForeName>P&#xe1;l</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perge</LastName><ForeName>Bianka</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varga</LastName><ForeName>&#xc9;va</ForeName><Initials>&#xc9;</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Hematology, Semmelweis University, 1083 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harangi</LastName><ForeName>Mariann</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9761-9595</Identifier><AffiliationInfo><Affiliation>Division of Metabolic Diseases, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ELKH-UD Vascular Pathophysiology Research Group 11003, University of Debrecen, 4032 Debrecen, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarr</LastName><ForeName>T&#xfc;nde</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008074">Lipoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059168" MajorTopicYN="Y">Carotid Intima-Media Thickness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063177" MajorTopicYN="N">Pulse Wave Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008074" MajorTopicYN="N">Lipoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="N">Triglycerides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">augmentation index</Keyword><Keyword MajorTopicYN="N">carotid intima-media thickness</Keyword><Keyword MajorTopicYN="N">flow-mediated dilation</Keyword><Keyword MajorTopicYN="N">intermediate-density lipoprotein</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">triglyceride</Keyword><Keyword MajorTopicYN="N">triglyceride-rich lipoproteins</Keyword><Keyword MajorTopicYN="N">very low-density lipoprotein</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36979336</ArticleId><ArticleId IdType="pmc">PMC10046254</ArticleId><ArticleId IdType="doi">10.3390/biom13030401</ArticleId><ArticleId IdType="pii">biom13030401</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bello N., Meyers K.J., Workman J., Hartley L., McMahon M. Cardiovascular events and risk in patients with systemic lupus erythematosus: Systematic literature review and meta-analysis. Lupus. 2022. online ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221147471</ArticleId><ArticleId IdType="pmc">PMC10012401</ArticleId><ArticleId IdType="pubmed">36547368</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenfeld S.R., Kasturi S., Costenbader K.H. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: A systematic review. Semin. Arthritis Rheum. 2013;43:77&#x2013;95. doi: 10.1016/j.semarthrit.2012.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2012.12.002</ArticleId><ArticleId IdType="pubmed">23422269</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinicato N.A., da Silva Cardoso P.A., Appenzeller S. Risk factors in cardiovascular disease in systemic lupus erythematosus. Curr. Cardiol. Rev. 2013;9:15&#x2013;19. doi: 10.2174/157340313805076304.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157340313805076304</ArticleId><ArticleId IdType="pmc">PMC3584302</ArticleId><ArticleId IdType="pubmed">23463953</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiss A.B., Jacob B., Ahmed S., Carsons S.E., DeLeon J. Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention. Inflammation. 2021;44:1663&#x2013;1682. doi: 10.1007/s10753-021-01455-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-021-01455-6</ArticleId><ArticleId IdType="pubmed">33821395</ArticleId></ArticleIdList></Reference><Reference><Citation>Atta A.M., Silva J.P.C.G., Santiago M.B., Oliveira I.S., Oliveira R.C., Sousa Atta M.L.B. Clinical and laboratory aspects of dyslipidemia in Brazilian women with systemic lupus erythematosus. Clin. Rheumatol. 2018;37:1539&#x2013;1546. doi: 10.1007/s10067-018-4051-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-018-4051-0</ArticleId><ArticleId IdType="pubmed">29516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W., Li P., Cai J., Ma J., Zhang X., Song Y., Liu Y. Lipid Metabolism: Immune Regulation and Therapeutic Prospectives in Systemic Lupus Erythematosus. Front. Immunol. 2022;13:860586. doi: 10.3389/fimmu.2022.860586.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.860586</ArticleId><ArticleId IdType="pmc">PMC8971568</ArticleId><ArticleId IdType="pubmed">35371016</ArticleId></ArticleIdList></Reference><Reference><Citation>Yelnik C.M., Martin C., Ledoult E., Sanges S., Sobanski V., Farhat M., Morell-Dubois S., Maillard H., Drumez E., Launay D., et al. Dyslipidemia is insufficiently treated in antiphospholipid syndrome patients. Lupus. 2022;31:1379&#x2013;1384. doi: 10.1177/09612033221114275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221114275</ArticleId><ArticleId IdType="pubmed">35822929</ArticleId></ArticleIdList></Reference><Reference><Citation>Borba E.F., Carvalho J.F., Bonf&#xe1; E. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. Clin. Dev. Immunol. 2006;13:203&#x2013;208. doi: 10.1080/17402520600876945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17402520600876945</ArticleId><ArticleId IdType="pmc">PMC2270754</ArticleId><ArticleId IdType="pubmed">17162363</ArticleId></ArticleIdList></Reference><Reference><Citation>Ga&#xe1;l K., Tarr T., L&#x151;rincz H., Borb&#xe1;s V., Seres I., Harangi M., F&#xfc;l&#xf6;p P., Paragh G. High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus. Lipids Health Dis. 2016;15:60. doi: 10.1186/s12944-016-0229-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12944-016-0229-0</ArticleId><ArticleId IdType="pmc">PMC4802594</ArticleId><ArticleId IdType="pubmed">27004558</ArticleId></ArticleIdList></Reference><Reference><Citation>Szab&#xf3; M.Z., Szodoray P., Kiss E. Dyslipidemia in systemic lupus erythematosus. Immunol. Res. 2017;65:543&#x2013;550. doi: 10.1007/s12026-016-8892-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-016-8892-9</ArticleId><ArticleId IdType="pubmed">28168401</ArticleId></ArticleIdList></Reference><Reference><Citation>Olusi S.O., George S. Prevalence of LDL atherogenic phenotype in patients with systemic lupus erythematosus. Vasc. Health Risk Manag. 2011;7:75&#x2013;80. doi: 10.2147/VHRM.S17015.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/VHRM.S17015</ArticleId><ArticleId IdType="pmc">PMC3049542</ArticleId><ArticleId IdType="pubmed">21415920</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg I.J. Lipoprotein lipase and lipolysis: Central roles in lipoprotein metabolism and atherogenesis. J. Lipid. Res. 1996;37:693&#x2013;707. doi: 10.1016/S0022-2275(20)37569-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2275(20)37569-6</ArticleId><ArticleId IdType="pubmed">8732771</ArticleId></ArticleIdList></Reference><Reference><Citation>Borato D.C., Parabocz G.C., Ribas J.T., Netto H.P., Erdmann F.C., Wiecheteck L.D., Manente F.A., Mello L.R., Bell&#xf3; C., dos Santos F.A., et al. Biomarkers in Obesity: Serum Myeloperoxidase and Traditional Cardiac Risk Parameters. Exp. Clin. Endocrinol. Diabetes. 2016;124:49&#x2013;54. doi: 10.1055/s-0035-1565093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0035-1565093</ArticleId><ArticleId IdType="pubmed">26797862</ArticleId></ArticleIdList></Reference><Reference><Citation>Quevedo-Abeledo J.C., Mart&#xed;n-Gonz&#xe1;lez C., Ferrer-Moure C., de Armas-Rillo L., Hernandez-Hernandez M.V., Gonz&#xe1;lez-Gay M., Ferraz-Amaro I. Key Molecules of Triglycerides Pathway Metabolism Are Disturbed in Patients With Systemic Lupus Erythematosus. Front. Immunol. 2022;13:827355. doi: 10.3389/fimmu.2022.827355.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.827355</ArticleId><ArticleId IdType="pmc">PMC9124762</ArticleId><ArticleId IdType="pubmed">35615358</ArticleId></ArticleIdList></Reference><Reference><Citation>Solt&#xe9;sz P., Kerekes G., D&#xe9;r H., Sz&#xfc;cs G., Sz&#xe1;nt&#xf3; S., Kiss E., Bodolay E., Zeher M., Tim&#xe1;r O., Szodoray P., et al. Comparative assessment of vascular function in autoimmune rheumatic diseases: Considerations of prevention and treatment. Autoimmun. Rev. 2011;10:416&#x2013;425. doi: 10.1016/j.autrev.2011.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2011.01.004</ArticleId><ArticleId IdType="pubmed">21281743</ArticleId></ArticleIdList></Reference><Reference><Citation>Cypiene A., Kovaite M., Venalis A., Dadoniene J., Rugiene R., Petrulioniene Z., Ryliskyte L., Laucevicius A. Arterial wall dysfunction in systemic lupus erythematosus. Lupus. 2009;18:522&#x2013;529. doi: 10.1177/0961203308099625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203308099625</ArticleId><ArticleId IdType="pubmed">19395454</ArticleId></ArticleIdList></Reference><Reference><Citation>Boros C.A., Bradley T.J., Cheung M.M., Bargman J.M., Russell J.L., McCrindle B.W., Adeli K., Hamilton J., Silverman E.D. Early determinants of atherosclerosis in paediatric systemic lupus erythematosus. Clin. Exp. Rheumatol. 2011;29:575&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">21640055</ArticleId></ArticleIdList></Reference><Reference><Citation>Svenungsson E., Cederholm A., Jensen-Urstad K., Fei G.Z., de Faire U., Frosteg&#xe5;rd J. Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus. Scand. J. Rheumatol. 2008;37:352&#x2013;359. doi: 10.1080/03009740802007514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03009740802007514</ArticleId><ArticleId IdType="pubmed">18666029</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmieri V., Migliaresi P., Orefice M., Lupo T., Di Minno M.N., Valentini G., Celentano A. High prevalence of subclinical cardiovascular abnormalities in patients with systemic lupus erythematosus in spite of a very low clinical damage index. Nutr. Metab. Cardiovasc. Dis. 2009;19:234&#x2013;240. doi: 10.1016/j.numecd.2008.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.numecd.2008.09.009</ArticleId><ArticleId IdType="pubmed">19157818</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiss E., Soltesz P., Der H., Kocsis Z., Tarr T., Bhattoa H., Shoenfeld Y., Szegedi G. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J. Autoimmun. 2006;27:211&#x2013;217. doi: 10.1016/j.jaut.2006.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2006.09.008</ArticleId><ArticleId IdType="pubmed">17088047</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacciapaglia F., Zardi E.M., Coppolino G., Buzzulini F., Margiotta D., Arcarese L., Vadacca M., Amoroso A., Afeltra A. Stiffness parameters, intima-media thickness and early atherosclerosis in systemic lupus erythematosus patients. Lupus. 2009;18:249&#x2013;256. doi: 10.1177/0961203308097571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203308097571</ArticleId><ArticleId IdType="pubmed">19213864</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanlo-Maresma M., Cand&#xe1;s-Est&#xe9;banez B., Esteve-Luque V., Padr&#xf3;-Miquel A., Escrihuela-Vidal F., Carratini-Moraes M., Corbella E., Corbella X., Pint&#xf3; X. Asymptomatic Carotid Atherosclerosis Cardiovascular Risk Factors and Common Hypertriglyceridemia Genetic Variants in Patients with Systemic Erythematosus Lupus. J. Clin. Med. 2021;10:2218. doi: 10.3390/jcm10102218.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10102218</ArticleId><ArticleId IdType="pmc">PMC8160900</ArticleId><ArticleId IdType="pubmed">34065555</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M., Costenbader K., Daikh D., Brinks R., Mosca M., Ramsey-Goldman R., Smolen J.S., Wofsy D., Boumpas D.T., Kamen D.L., et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71:1400&#x2013;1412. doi: 10.1002/art.40930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Celermajer D.S., Sorensen K.E., Gooch V.M., Spiegelhalter D.J., Miller O.I., Sullivan I.D., Lloyd J.K., Deanfield J.E. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111&#x2013;1115. doi: 10.1016/0140-6736(92)93147-F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0140-6736(92)93147-F</ArticleId><ArticleId IdType="pubmed">1359209</ArticleId></ArticleIdList></Reference><Reference><Citation>Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., Deanfield J., Drexler H., Gerhard-Herman M., Herrington D., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J. Am. Coll. Cardiol. 2002;39:257&#x2013;265. doi: 10.1016/S0735-1097(01)01746-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(01)01746-6</ArticleId><ArticleId IdType="pubmed">11788217</ArticleId></ArticleIdList></Reference><Reference><Citation>Szucs G., T&#xed;m&#xe1;r O., Szekanecz Z., D&#xe9;r H., Kerekes G., Szamosi S., Shoenfeld Y., Szegedi G., Solt&#xe9;sz P. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis--relevance for prevention of vascular complications. Rheumatology. 2007;46:759&#x2013;762. doi: 10.1093/rheumatology/kel426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kel426</ArticleId><ArticleId IdType="pubmed">17244666</ArticleId></ArticleIdList></Reference><Reference><Citation>Baulmann J., Schillings U., Rickert S., Uen S., D&#xfc;sing R., Illyes M., Cziraki A., Nickering G., Mengden T. A new oscillometric method for assessment of arterial stiffness: Comparison with tonometric and piezo-electronic methods. J. Hypertens. 2008;26:523&#x2013;528. doi: 10.1097/HJH.0b013e3282f314f7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0b013e3282f314f7</ArticleId><ArticleId IdType="pubmed">18300864</ArticleId></ArticleIdList></Reference><Reference><Citation>Magometschnigg D. Blood pressure and arterial stiffness. A comparison of two devices for measuring augmentationindex and pulse wave velocity. Wien Med. Wochenschr. 2005;155:404&#x2013;410. doi: 10.1007/s10354-005-0209-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10354-005-0209-x</ArticleId><ArticleId IdType="pubmed">16392438</ArticleId></ArticleIdList></Reference><Reference><Citation>Horv&#xe1;th I.G., N&#xe9;meth A., Lenkey Z., Alessandri N., Tufano F., Kis P., Gaszner B., Czir&#xe1;ki A. Invasive validation of a new oscillometric device (Arteriograph) for measuring augmentation index, central blood pressure and aortic pulse wave velocity. J. Hypertens. 2010;28:2068&#x2013;2075. doi: 10.1097/HJH.0b013e32833c8a1a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0b013e32833c8a1a</ArticleId><ArticleId IdType="pubmed">20651604</ArticleId></ArticleIdList></Reference><Reference><Citation>Salinas C.A.A., Chapman M.J. Remnant lipoproteins: Are they equal to or more atherogenic than LDL? Curr. Opin. Lipidol. 2020;31:132&#x2013;139. doi: 10.1097/MOL.0000000000000682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOL.0000000000000682</ArticleId><ArticleId IdType="pubmed">32332433</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman M.J., Laplaud P.M., Luc G., Forgez P., Bruckert E., Goulinet S., Lagrange D. Further resolution of the low density lipoprotein spectrum in normal human plasma: Physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J. Lipid Res. 1988;29:442&#x2013;458. doi: 10.1016/S0022-2275(20)38518-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2275(20)38518-7</ArticleId><ArticleId IdType="pubmed">3392462</ArticleId></ArticleIdList></Reference><Reference><Citation>Proctor S.D., Vine D.F., Mamo J.C. Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy. Arter. Thromb. Vasc. Biol. 2004;24:2162&#x2013;2167. doi: 10.1161/01.ATV.0000143859.75035.5a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.0000143859.75035.5a</ArticleId><ArticleId IdType="pubmed">15345509</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo-N&#xfa;&#xf1;ez Y., Morales-Villegas E., Aguilar-Salinas C.A. Triglyceride-Rich Lipoproteins: Their Role in Atherosclerosis. Rev. Invest. Clin. 2022;74:061&#x2013;070. doi: 10.24875/RIC.21000416.</Citation><ArticleIdList><ArticleId IdType="doi">10.24875/RIC.21000416</ArticleId><ArticleId IdType="pubmed">34759386</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordestgaard B.G., Tybjaerg-Hansen A. IDL, VLDL, chylomicrons and atherosclerosis. Eur. J. Epidemiol. 1992;8((Suppl. S1)):92&#x2013;98. doi: 10.1007/BF00145358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00145358</ArticleId><ArticleId IdType="pubmed">1505659</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson G.A., Peng J., Pineda-Torra I., Ciurtin C., Jury E.C. Metabolomics Defines Complex Patterns of Dyslipidaemia in Juvenile-SLE Patients Associated with Inflammation and Potential Cardiovascular Disease Risk. Metabolites. 2021;12:3. doi: 10.3390/metabo12010003.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo12010003</ArticleId><ArticleId IdType="pmc">PMC8779263</ArticleId><ArticleId IdType="pubmed">35050125</ArticleId></ArticleIdList></Reference><Reference><Citation>Svensson C., Eriksson P., Bjarneg&#xe5;rd N., Jonasson H., Str&#xf6;mberg T., Sj&#xf6;wall C., Zachrisson H. Impaired Microcirculation and Vascular Hemodynamics in Relation to Macrocirculation in Patients With Systemic Lupus Erythematosus. Front. Med. 2021;8:722758. doi: 10.3389/fmed.2021.722758.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.722758</ArticleId><ArticleId IdType="pmc">PMC8591084</ArticleId><ArticleId IdType="pubmed">34790671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendoza-Pinto C., Rojas-Villarraga A., Molano-Gonz&#xe1;lez N., Garc&#xed;a-Carrasco M., Mungu&#xed;a-Realpozo P., Etchegaray-Morales I., Morales-S&#xe1;nchez H., Berra-Romani R., Cervera R. Endothelial dysfunction and arterial stiffness in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Atherosclerosis. 2020;297:55&#x2013;63. doi: 10.1016/j.atherosclerosis.2020.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2020.01.028</ArticleId><ArticleId IdType="pubmed">32078830</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan H.C., Liang C.J., Lee H.C., Su H., Lee A.S., Shiea J., Tsai W.C., Ou T.T., Wu C.C., Chu C.S., et al. Role of Low-Density Lipoprotein in Early Vascular Aging Associated With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020;72:972&#x2013;984. doi: 10.1002/art.41213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41213</ArticleId><ArticleId IdType="pubmed">31994323</ArticleId></ArticleIdList></Reference><Reference><Citation>Tselios K., Koumaras C., Gladman D.D., Urowitz M.B. Dyslipidemia in systemic lupus erythematosus: Just another comorbidity? Semin. Arthritis Rheum. 2016;45:604&#x2013;610. doi: 10.1016/j.semarthrit.2015.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2015.10.010</ArticleId><ArticleId IdType="pubmed">26711309</ArticleId></ArticleIdList></Reference><Reference><Citation>Graziadei I.W., Obermoser G.E., Sepp N.T., Erhart K.H., Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus. 2003;12:409&#x2013;412. doi: 10.1191/0961203303lu313cr.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203303lu313cr</ArticleId><ArticleId IdType="pubmed">12765306</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadstr&#xf6;m B.N., Pedersen K.M., Wulff A.B., Nordestgaard B.G. Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality. Eur. Heart J. 2023:ehac822. doi: 10.1093/eurheartj/ehac822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac822</ArticleId><ArticleId IdType="pubmed">36631967</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>